Clinical Neuropsychopharmacology and Therapeutics
Online ISSN : 1884-8826
ISSN-L : 1884-8826
Original Contribution
Improvement in antipsychotic-induced hyperprolactinemia with the addition of aripiprazole in schizophrenic patients
Kazuo MiharaGoyo NagaiAkifumi NakamuraYasuhide FukujiTakeshi SuzukiTsuyoshi Kondo
Author information

2010 Volume 1 Pages 1-5


Purpose: Hyperprolactinemia, a common adverse effect of antipsychotics, frequently impacts patients' quality of life. Aripiprazole is a potent dopamine D2 receptor partial agonist and rarely increases the serum prolactin concentration. The authors investigated the effect of aripiprazole coadministration on antipsychotic-induced hyperprolactinemia and associated symptoms in patients with schizophrenia.
Method: The subjects were 9 patients (8 females, 1 male) with hyperprolactinemia induced by risperidone, olanzapine, haloperidol, zotepine, bromperidol, levomepromazine, and quetiapine; 6 of the females had oligomenorrhea and 2 amenorrhea, and the male had erectile dysfunction. All of the patients received concomitant aripiprazole for more than 8 weeks at a mean dose (range) of 7.7 (3-18) mg/day. The doses of all other medications, including the hyperprolactinemia-inducing antipsychotics, remained fixed throughout the study period.
Results: The mean serum concentration (range) of prolactin during aripiprazole coadministration (29.9 (9.8-53) ng/ml) was significantly (p=0.008) lower than that before aripiprazole coadministration (81.1(27-153) ng/ml). The associated symptoms were improved in 4 females (regularized or regained menstruation) and the male (normalized erectile function), while no changes were observed in the other clinical symptoms of schizophrenia.
Discussion: The results of the present study suggest that even small doses of coadministered aripiprazole effectively limit excessive prolactin response to antipsychotics without interfering with the benefits of existing prescriptions.

Content from these authors
© 2010 The Japanese Society of Clinical Neuropsychopharmacology
Previous article Next article